Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Disulfiram
Drug ID BADD_D00695
Description A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Indications and Usage For the treatment and management of chronic alcoholism
Marketing Status approved
ATC Code N07BB01; P03AA04
DrugBank ID DB00822
KEGG ID D00131
MeSH ID D004221
PubChem ID 3117
TTD Drug ID D0X5SD
NDC Product Code 42973-137; 71052-221; 42794-028; 0054-0357; 73309-150; 51927-3121; 62135-432; 64980-171; 0054-0356; 38779-1971; 65571-0005; 62135-431; 64980-172; 51927-0188; 72643-028; 47781-607; 60429-196
UNII TR3MLJ1UAI
Synonyms Disulfiram | Bis(diethylthiocarbamoyl) Disulfide | Tetraethylthioperoxydicarbonic Diamide, ((H2N)C(S))2S2 | Tetraethylthiuram Disulfide | Disulfide, Tetraethylthiuram | Antabus | Antabuse | Teturam | Dicupral | Esperal | Alcophobin | Anticol
Chemical Information
Molecular Formula C10H20N2S4
CAS Registry Number 97-77-8
SMILES CCN(CC)C(=S)SSC(=S)N(CC)CC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001---
Abdominal pain07.01.05.0020.005665%
Alcohol intolerance14.02.01.0010.009442%
Anxiety19.06.02.0020.007553%
Arthralgia15.01.02.0010.022660%
Asthenia08.01.01.001---
Breath odour07.01.06.002---
Catatonia19.11.01.0010.003777%-
Cerebral infarction17.08.01.004; 24.04.06.0020.003777%-
Condition aggravated08.01.03.0040.003777%-
Delirium19.13.02.0010.003777%
Delusion19.10.01.0010.007553%
Dermatitis acneiform23.02.01.004--
Dermatitis allergic10.01.03.014; 23.03.04.003---
Dermatitis atopic10.01.04.004; 23.03.04.016---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug interaction08.06.03.0010.018884%-
Dysgeusia07.14.03.001; 17.02.07.003--
Encephalopathy17.13.02.0010.009442%
Epilepsy17.12.03.0020.003777%-
Eye pain06.08.03.002--
Fatigue08.01.01.0020.069869%
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.0160.003777%
Generalised tonic-clonic seizure17.12.01.0020.016995%-
Hallucination19.10.04.0030.008309%
Headache17.14.01.001--
Hepatic cirrhosis09.01.04.0010.003777%-
Hepatic encephalopathy09.01.03.006; 17.13.01.0030.003777%-
Hepatic failure09.01.03.002--
Hepatic necrosis09.01.07.0020.003777%
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene